MedGenome Inc.’s Monoclonal Antibody Discovery Services
Antibody discovery is important for early stage research studies, diagnostics and therapeutics. Hybridoma technology has been the mainstay to generate monoclonal antibodies. MedGenome has streamlined antibody discovery using high-throughput single B cell receptor sequencing and a recently licensed proprietary platform, HiTMab* (High-throughput monoclonal antibody discovery).
T-cell activation assay combined with single-cell TCR sequencing
MedGenome’s OncoPeptSCRN and OncoPeptTCR assays are integrated to provide a seamless platform for identifying antigen-specific TCRs. Additional characterization of the TCRs by cloning and expression are available as part of the TCR analysis service.
OncoPept Platform Technology for the Discovery of Potent T-cell Activating Epitopes Against Naturally Processed Antigen
OncoPeptSCRN is a robust, high throughput and cost-effective assay platform to screen peptides for their T-cell activity. Peptides strongly activating T-cells have therapeutic utility as vaccines and as immune monitoring reagents. The screening platform is highly sensitive in detecting many T-cell markers to predict their phenotypic state and their ability to kill target cells. OncoPeptSCRN combines two assay formats in which epitopes are provided as synthetic peptides, or are expressed inside the cells to mimic natural processing and presentation. The platform is highly optimized for discovering HLA-peptide pairs having robust T-cell activation properties facilitating the discovery of potent therapeutic engagers. OncoPeptSCRN assay platform combines technological advancements in genomics and proteomics for the discovery of strong T-cell activating epitopes - the holy grail of modern vaccinology.
A platform-agnostic approach to single-cell genomic applications
Single cell genomics is a powerful approach to uncover cellular heterogeneity in normal and disease tissues, and understanding molecular mechanisms of development and disease. However, preparing samples for processing and isolating or capturing a sufficient number of single cells to be able to answer the research question of interest is challenging. The wide ranges of tissue architecture, and cellular sizes and shapes calls for the availability of platforms that can efficiently recover sufficient numbers of single cells for the assays of interest. In addition to the diversity in cell sizes and shapes, there is a wide range of starting numbers of cells and viability that is available for processing. In order to ensure successful generation of single cell libraries from a wide range of starting material, at MedGenome we have integrated several of the well-validated single cell isolation and library preparation platforms.
Denovo Genome Assembly Solutions at MedGenome
The Whitepaper explores MedGenome's experience in genomics technologies in developing a comprehensive, customizable service for high-quality genome assembly and annotation.
MedGenome Inc. Broadens NGS offerings with Loop Genomics Metagenomics Service
The whitepaper discusses how MedGenome utilizes Loop Genomics technology for 16S long-read sequencing that covers the entire V1-V9 regions in a single read that are classified at the species or genus level, with zero false-positive assignments.
Human B-cell Receptor Profiling service at MedGenome Inc.
Epigenomic profiling solutions at MedGenome
Single Cell PLATE Seq Solutions at MedGenome
In this white paper we discuss a robust and cost-effective solution for generating single cell RNA seq data from FACS sorted cells using the full-length SMART seq chemistry. This approach is useful when there is a limited number of cells available, or cells that have larger sizes and the capture efficiencies can be lower using the droplet based approaches. We have validated this approach and find that we can identify cellular heterogeneity and identify cell types from few hundred cells.
Human Bulk BCR Profiling Technical Sheet
At MedGenome, we provide BCR repertoire profiling from bulk input (from cells & RNA) using the SMARTer BCR Profiling Kit (Takara Bio USA Inc) and single-cell inputs using the Chromium Immune Profiling solutions (10X Genomics). The sample types we have validated include frozen PBMCs, hybridoma and spleen. We follow the manufacturers recommended guidelines for our quality control at every step of the process and provide customers with accurate QC reports. In addition, we support experimental design and basic and advanced analysis.
TCR sequencing solutions at MedGenome
In this whitepaper, we present MedGenome’s NGS based workflows for profiling of the TCR repertoire: namely a) Bulk TCR profiling using: SMARTer TCR α /β Profiling Kit (Takara Bio USA Inc) and modifications to the protocol for Gamma/Delta and FFPE TCR repertoire profiling, b) Single cell TCR Profiling using: 10X Genomics Chromium Immune Profiling solutions, and Takara single-cell TCR sequencing kits. We also present an overview of the types of samples we have processed in-house and application.
T Cell Receptor (TCR) Repertoire Sequencing
In this technical sheet, we present information on the workflows for TCR sequencing at MedGenome and also present the sample types that we can process. We also present application data using SMARTer TCR α/β Profiling Kit and 10x Genomics chromium platform downstream of neoantigen vaccine screening platform developed at MedGenome : OncoPeptVAC.
T Cell Receptor (TCR) repertoire sequencing from FFPE samples
In this white-paper we present data generated by using a modified protocol of the SMARTer® TCR Proﬁling Kit to perform TCR sequencing and analysis of tumor-infiltrating lymphocytes (TILs) from a FFPE tumor tissue block.
We accept sample both as RNA (100 ng minimum) or 5 μm unstained FFPE tumor tissue blocks.
OncoPeptTUMETM — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications
Cancer immunotherapy is now established as a major therapeutic modality, and 70% of all cancer patients are estimated to receive some form of immunotherapy treatment as a part of their disease control by 2025. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated patients by activating CD8 T-cells and provide sustainable and long-lasting benefit in a few. Recently significant efforts have been devoted to understanding the factors that influence response to immuno-therapy or contribute to the development of resistance to therapy. While it is appreciated that many different tumor cell- intrinsic and extrinsic features, including the tumor microenvironment, driver gene mutations, host genetics, microbiome and environmental factors modulate response to immune checkpoint inhibitors , the tumor microenvironment ecosystem could be a major contributor in regulating response to immunotherapy and development of resistance [2,3].
Ophthatome Knowledgebase: Over 500,000 Clinical Phenotype Records for Ocular Research
To enable genomic, pharmacogenomic and clinical research and discovery for ocular diseases, MedGenome has launched the OphthatomeTM Knowledgebase. This knowledgebase of ocular diseases is a comprehensive collection of clinical, phenotype and biochemical data providing researchers and clinicians with a platform to design studies that address critical unmet needs in eye disorders. The searchable interface allows end users to build complex queries to select disease cohorts based on organs affected, disease type and subtype, the age of disease onset, drug response and many other clinical and phenotypic parameters.